Abstract
Cancer is one of the most dominant global health concerns, and the field of cancer therapeutics is in an era of rapid expansion. It is thus critical that the system for evaluating the effectiveness of new cancer treatments be accurate, standardized, and applied to clinical research across healthcare systems.
RECIST is a set of published rules that define when cancer patients with solid tumors “respond,” “stabilize,” or “progress” during treatments. Below is a summary of the current guidelines for the assessment of tumor response to antineoplastic therapies including special considerations such as evaluation of immune therapies and malignancies involving the central nervous system. Also reviewed are different assessment techniques and the rationalization of standardization of assessment systems.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors (RECIST guidelines). J Natl Cancer Inst. 2000;92:205–16.
Eisenhauer E, Therasse P, Bogaerts l, et al. New responses evaluation criteria in solid tumours: revised RECIST guidelines (version 1.1). Eur J Cancer. 2009;45:228–47.
Schwartz LH, Litiere S, de Vries E, et al. RECIST 1.1- update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132–7.
Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.
Topalian SL, Drake C, Pardoll D. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450–61.
Pardoll D. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64.
Seymour L, Bogaerts J, Perrone A, et al. iRecist: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:143–52.
Wolchok JD, Hoos A, O’Day S, et al. Guideline for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Cancer Therapy. 2009;15:7412–20.
Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med. 2006;354:496–507.
ZinZani P, Tani M, Alinari S, et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin’s disease patients. Ann Oncol. 2006;17:1296–300.
Wahl R, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50:122–50.
Dehdashti F, Flanagan FL, Mortimer JE, Katzenellenbogen JA, Welch MJ, Siegel BA. Positron emission tomographic assessment of “metabolic flare” to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med. 1999;26:51–6.
Bos R, van Der Hoeven JJ, van der WE, et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;20:379–87.
Cerfolio R, Bryant A, Winokur T, et al. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg. 2004;78:1903–9.
Shankar LK, Hoffman JM, Bacharach S, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med. 2006;47:1059–66.
MacDonald DR, Cascino TL, Scold SC, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277–80.
Wen P, Macdonald D, Reardon D, et al. Update response assessment criteria for hight-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963–72.
Lin N, Aoyama H, Barani I, et al. Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol. 2015;16:e270–8.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Lathrop, K., Kaklamani, V. (2019). The Response Evaluation Criteria in Solid Tumors (RECIST). In: Badve, S., Kumar, G. (eds) Predictive Biomarkers in Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-95228-4_46
Download citation
DOI: https://doi.org/10.1007/978-3-319-95228-4_46
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-95227-7
Online ISBN: 978-3-319-95228-4
eBook Packages: MedicineMedicine (R0)